Highlights
- •The correlations among signal absolute enhancement, contrast enhancement ratio (CER) and histological grade were analyzed.
- •We use CER of tumor-to-liver calculated by the equation SIth − SItu/SIlh − SIlu to evaluate Gd-EOB-DTPA-enhanced MRI.
- •We use the value of contrast enhancement ratio of tumor-to-liver to predict histological grades of small HCCs.
Abstract
Objective
To confirm the histological grade of hepatocellular carcinoma (HCC) by gadoxetic acid-enhanced
MRI.
Methods
Ninety-five HCC patients underwent gadoxetic acid-enhanced MRI before surgical intervention.
The correlations among the signal absolute enhancement, contrast enhancement ratio
(CER) and tumor histological grade were analyzed.
Results
The correlation between CER of tumor-to-liver and the grades of tumor differentiation
is the most significant negative. The k-value for the CER of tumor-to-liver and histopathologic
analysis is 0.62, which gives evidence of good agreement.
Conclusion
The quantitative analysis of gadoxetic acid-enhanced MRI can predict the histological
grades of small HCCs.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of hepatocellular carcinoma in USA.Hepatol Res. 2007; 37: S88-S94
- Global cancer statistics, 2012.CA Cancer J Clin. 2015; 65: 87-108
- Liver cancer.in: Schottenfeld D. Fraumeni J.J. Cancer epidemiology and prevention. 3rd ed. Oxford University Press, New York2006: 763-786
- Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.Eur Radiol. 2009; 19: 342-357
- Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.Radiology. 1992; 183: 59-64
- Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.Radiology. 2005; 237: 89-98
- Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.Acta Radiol. 2007; 48: 362-368
- Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.Magn Reson Imaging. 2012; 30: 356-360
- The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging.Eur Radiol. 2011; 21: 2056-2066
- Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.Eur Radiol. 2008; 18: 457-467
- Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.Magn Reson Med Sci. 2005; 4: 1-9
- Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.Am J Roentgenol. 2011; 197: 399-405
- Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.Am J Roentgenol. 2009; 193: 1053-1060
- Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation.Am J Roentgenol. 2013; 201: W603-W611
- Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection.Ann Surg. 2009; 249: 118-123
- Terminology of nodular hepatocellular lesions.Hepatology. 1995; 22: 983-993
- Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.Cancer. 1954; 7: 462-503
- The measurement of observer agreement for categorical data.Biometrics. 1977; 33: 159-174
- Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations.Radiology. 2005; 234: 468-478
- Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus.Liver Cancer. 2014; 3: 97-107
- Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.J Gastroenterol. 2009; 44: 793-798
- Primovist, Eovist: what to expect?.J Hepatol. 2012; 57: 421-429
- The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.J Hepatol. 2004; 40: 212-218
- Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.Radiology. 1996; 199: 177-183
- Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma.Gut Liver. 2011; 5: 15-21
- Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI.PLoS One. 2014; 9e100315https://doi.org/10.1371/journal.pone.0100315
- Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.Hepatology. 2014; 60: 1674-1685
- Clinicopathologic features of poorly differentiated hepatocellular carcinoma.J Surg Oncol. 2007; 95: 311-316
Article info
Publication history
Published online: January 13, 2017
Accepted:
December 19,
2016
Received in revised form:
December 15,
2016
Received:
September 24,
2016
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
